VerImmune, a biotechnology company developing new therapeutic modalities that aim to redirect the body's pre-existing immunity toward cancer, announced the close of $2.5 million in Seed funding. The round was led by SeedFolio.

The round also included participation from US and global investment venture firms such as Ulu Ventures, and Proxima VC as well as leading private investment syndicate funds such as the NuFund Venture group (previously Tech Coast Angels- San Diego), Gaingels, Mana Ventures, and others.